Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.5K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

603
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
603
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

991
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
991

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glial-modulating agents for the treatment of pain: a systematic review.

Pain·2024
Same author

Ketamine for Cancer Pain: Re. Systematic Review by Jiao et al.

Journal of pain and symptom management·2024
Same author

Effectiveness of non-pharmacological interventions for fibromyalgia and quality of review methods: an overview of Cochrane Reviews.

Seminars in arthritis and rheumatism·2023
Same author

Trials We Cannot Trust: Investigating Their Impact on Systematic Reviews and Clinical Guidelines in Spinal Pain.

The journal of pain·2023
Same author

Characteristics of retracted publications related to pain research: a systematic review.

Pain·2023
Same author

Cannabis-based medicines and medical cannabis for adults with cancer pain.

The Cochrane database of systematic reviews·2023

Related Experiment Video

Updated: Apr 23, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

19.1K

Eletriptan for acute migraine headaches in adults.

Sheena Derry1, R Andrew Moore1, Henry J McQuay1

  • 1Pain Research and Nuffield Department of Anaesthetics, University of Oxford, Oxford, UK.

The Cochrane Database of Systematic Reviews
|October 1, 2014
PubMed
Summary

This review will assess eletriptan's effectiveness and safety for acute migraine headaches in adults. It compares eletriptan against placebo and other treatments to determine optimal migraine management strategies.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K

Related Experiment Videos

Last Updated: Apr 23, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

19.1K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Migraine is a common neurological disorder.
  • Acute treatment options are varied.
  • Eletriptan is a triptan medication for migraine.

Purpose of the Study:

  • To evaluate the efficacy of eletriptan in treating acute migraine headaches in adults.
  • To assess the tolerability and safety profile of eletriptan.
  • To compare eletriptan with placebo and other active migraine treatments.

Main Methods:

  • Systematic review and meta-analysis protocol.
  • Literature search of randomized controlled trials.
  • Data extraction on efficacy and tolerability outcomes.

Main Results:

  • Eletriptan's efficacy in pain relief and symptom resolution will be quantified.
  • Adverse event rates associated with eletriptan will be analyzed.
  • Comparative effectiveness of eletriptan versus other interventions will be determined.

Conclusions:

  • Evidence on eletriptan's role in acute migraine treatment will be synthesized.
  • Clinical implications for migraine management will be discussed.
  • Future research directions in migraine pharmacotherapy may be identified.